AGNES MARAMBA: Open Payments
NPI 1770158172 · KENT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,642 in 131 payments from 18 companies in 2025. Trend: 2023 $3,253 · 2024 $2,785 · 2025 $3,642
Food & beverage: $3,531Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $641 |
| Teva Pharmaceuticals USA, Inc. | 18 | $547 |
| ABBVIE INC. | 15 | $427 |
| Neurocrine BioSciences, Inc. | 8 | $293 |
| Vanda Pharmaceuticals Inc. | 8 | $289 |
| Alkermes, Inc. | 12 | $286 |
| Janssen Pharmaceuticals, Inc | 7 | $228 |
| Axsome Therapeutics, Inc. | 9 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
Products named: REXULTI, VRAYLAR, FANAPT, ARISTADA, INGREZZA, Auvelity, SPRAVATO, AUSTEDO XR.
Industry payments across WA — which companies pay providers there.
